News
PROK
1.780
+0.57%
0.010
Weekly Report: what happened at PROK last week (0504-0508)?
Weekly Report · 2d ago
ProKidney's Earnings Call Will Test Whether Biotech Investors Still Believe in Kidney Regeneration
Barchart · 2d ago
Weekly Report: what happened at PROK last week (0427-0501)?
Weekly Report · 05/04 10:34
Weekly Report: what happened at PROK last week (0420-0424)?
Weekly Report · 04/27 10:38
Weekly Report: what happened at PROK last week (0413-0417)?
Weekly Report · 04/20 10:33
Weekly Report: what happened at PROK last week (0406-0410)?
Weekly Report · 04/13 10:38
Weekly Report: what happened at PROK last week (0330-0403)?
Weekly Report · 04/06 10:38
Weekly Report: what happened at PROK last week (0323-0327)?
Weekly Report · 03/30 10:39
ProKidney appoints Greg Madison as chief commercial officer
TipRanks · 03/25 20:05
ProKidney appoints Greg Madison chief commercial officer; senior leadership team expands
Reuters · 03/25 20:01
Press Release: ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
Dow Jones · 03/25 20:01
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), LENZ Therapeutics (LENZ) and Sarepta Therapeutics (SRPT)
TipRanks · 03/25 15:10
Weekly Report: what happened at PROK last week (0316-0320)?
Weekly Report · 03/23 10:34
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability
TipRanks · 03/20 06:01
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)
TipRanks · 03/19 13:20
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)
TipRanks · 03/19 11:17
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating
TipRanks · 03/19 11:15
Guggenheim Sticks to Its Buy Rating for ProKidney (PROK)
TipRanks · 03/19 10:56
More
Webull provides a variety of real-time PROK stock news. You can receive the latest news about ProKidney through multiple platforms. This information may help you make smarter investment decisions.
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.